Jiamin Peng1
Yong Han- 1Department of Clinical Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China
- 2Department of Thoracic Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, China
- 3Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Hangzhou, Zhejiang, China
- 4Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China
Introduction
The blood–brain barrier (BBB) is a physical and biochemical boundary between the parenchyma of the central nervous system (CNS) and the bloodstream (Uchida et al., 2023). The BBB is a complex network of endothelial cells that line the brain’s capillaries, fortified by tight junctions, surrounded by a basement membrane, and supported by pericytes, microglia and astrocytes (Hynynen, 2024). This intricate structure serves as a guardian of the brain’s internal environment, meticulously regulating the passage of substances from the blood to the brain. Its selective permeability is crucial for maintaining neuronal homeostasis and shields the CNS from viruses, bacteria, and neurotoxins (Uchida et al., 2020; Terstappen et al., 2021; Uchida et al., 2022). However, this protective mechanism poses a significant challenge for the delivery of therapeutic agents to the brain. The BBB prevents 98% of small-molecule drugs and 100% of large-molecule drugs from entering the CNS, limiting treatment options for a wide range of neurological conditions (Hynynen, 2024). For instance, neurodegenerative diseases like Alzheimer’s and Parkinson’s require therapeutic agents that can target the brain’s affected regions. Similarly, treating brain tumors demands that chemotherapeutic agents traverse the BBB to reach malignant cells (Partridge et al., 2022).
The challenge of BBB permeabilization has spurred a multitude of research endeavors aimed at developing techniques to safely and transiently open this barrier, facilitating the delivery of drugs to the brain. Of them, non-invasive technologies such as MRI- guided focused ultrasound (MRgFUS) and Tumor Treating Fields (TTFields, based on Electric Field technology) emerge as promising solutions, offering a blend of safety, efficacy, and patient-centric design (Guo et al., 2022; Salvador et al., 2022; Meng et al., 2023).
Opinion
Old drugs that are previously excluded from the brain could be delivered to CNS through these temporarily BBB opening technologies for the treatment of brain diseases. In the future, new biopharmaceuticals such as antibody drugs will also be developed and delivered to the brain to treat CNS disorders including Alzheimer’s disease, Parkinson’s disease and glioblastomas.
Evidence to support this opinion
Recently, various technologies have been developed to deliver drugs to the CNS, some of which have entered clinical trials. In previously experimental models, the application of focused ultrasound to open the BBB resulted in a level of five to eight times high of aducanumab delivery to targeted brain regions in comparison to the untreated regions of the brain (Leinenga et al., 2021; Kong et al., 2022).
In an investigator-initiated, prospective, open-label, single-group, single-institution, proof-of-concept trial involving three patients that published in New England Journal of Medicine, Rezai et al. utilized magnetic resonance imaging (MRI)–guided focused ultrasound to temporarily open the BBB and enhance the delivery of aducanumab, which is an amyloid-binding monoclonal antibody with limited penetration of the BBB(2). The authors found that, during the 6-month combination-treatment phase, the reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than aducanumab therapy alone in homologous regions that were not treated with focused ultrasound (Rezai et al., 2024).
The BBB is a major challenge for malignant gliomas treatment, which limits the penetration of most chemotherapeutic drugs. Low-intensity pulsed ultrasound with concomitant administration of intravenous microbubbles (LIPU-MB) could temporarily open the BBB for drug delivery. In a dose-escalation phase 1 clinical trial in adults with recurrent glioblastoma that published in The Lancet Oncology, Sonabend et al. reported that the application of LIPU-MB to large areas of the brain to deliver albumin-bound paclitaxel across the BBB is safe and well tolerated. This work provides the first direct evidence that LIPU-MB could enhance the delivery of systemically administered large molecule drugs to the brain and significantly increase its brain concentration in human (Sonabend et al., 2023).
TTFields is a physical therapy that uses low-intensity and moderate frequency and alternating electric fields to inhibit tumors. The US Food and Drug Administration have approved TTFields for treating recurrent or newly diagnosed glioblastoma and malignant pleural mesothelioma (Tanzhu et al., 2022). Besides, TTFields could also reversibly permeabilize the BBB and enhance the delivery of BBB restricted drugs in vivo and in vitro (Salvador et al., 2022).
In conclusion, by making advantage of BBB opening technologies, old drugs that previously have limited access to the brain could be reconsidered for the management of CNS disorders.
Discussion and conclusion
The quest to overcome the BBB’s restrictive influence on drug delivery has led to the development of a diverse array of permeabilization techniques, each with its unique strengths and limitations. For instance, MRgFUS offers precise control over the area of the BBB disruption, allowing for targeted treatment with minimal impact on surrounding tissues. The non-invasive nature of this technology aligns with the growing demand for patient-friendly treatment modalities. The integration of MRI allows for real-time monitoring and precise targeting of ultrasound energy, enhancing the safety and efficacy of BBB permeabilization (Uchida et al., 2023). However, MRI is needed because energy from ultrasound could still potentially cause damages to brain cells and nerve. Analogous to LIPU, the impacts of MRgFUS are transient, demanding vigilant oversight to mitigate the risk of ultrasound-induced tissue harm. Moreover, MRgFUS technology entails substantial costs and necessitates operation by specialized personnel within clinical environments.
The continuous application of TTFields can be easily integrated into patients' daily lives, offering a non-invasive and ongoing treatment option. However, the necessity for uninterrupted therapy with TTFields could significantly affect patients' daily lives, posing challenges to their comfort and overall quality of life. Moreover, the enduring consequences of electric field exposure on non-targeted, healthy brain tissue remain to be thoroughly understood, necessitating extensive research. Additionally, the practical aspects of therapy, including the need for patients to shave their heads and secure electrodes to their scalp, may lead to discomfort, skin irritation, or rashes, further complicating the treatment experience.
In summary, large-volume BBB opening technologies are safe and reproducible, which means such procedures could be repeated over multiple cycles of chemotherapy. Benefit from these technologies, old drugs and large size biopharmaceuticals that previously could not pass BBB now can be easily delivered to the brain and could be considered for the treatment of CNS disorders such as Alzheimer’s disease, Parkinson’s disease and glioblastomas. Moreover, the R&D paradigm of drugs for brain diseases would change due to the repaid progress of BBB opening technologies. Nonetheless, since BBB opening or dysfunction might have certain side effects (Uchida et al., 2020; Uchida et al., 2022), the dynamic real-time monitoring of BBB permeability through BBB imaging technologies is highly required to ensure the precise sites of action and length of BBB opening time (Uchida et al., 2023).
Author contributions
JP: Conceptualization, Writing–original draft. YH: Project administration, Resources, Supervision, Writing–review and editing. LW: Conceptualization, Project administration, Writing–review and editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Guo, X., Yang, X., Wu, J., Yang, H., Li, Y., Li, J., et al. (2022). Tumor-treating fields in glioblastomas: past, present, and future. Cancers (Basel) 14 (15), 3669. Epub 2022/08/13. doi:10.3390/cancers14153669
Hynynen, K. (2024). Sounding out the blood-brain barrier. N. Engl. J. Med. 390 (1), 82–85. Epub 2024/01/04. doi:10.1056/NEJMe2311358
Kong, C., Yang, E. J., Shin, J., Park, J., Kim, S. H., Park, S. W., et al. (2022). Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model. Transl. Neurodegener. 11 (1), 57. Epub 2022/12/28. doi:10.1186/s40035-022-00333-x
Leinenga, G., Koh, W. K., and Götz, J. (2021). A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease. Alzheimers Res. Ther. 13 (1), 76. Epub 2021/04/11. doi:10.1186/s13195-021-00809-4
Meng, Y., Goubran, M., Rabin, J. S., McSweeney, M., Ottoy, J., Pople, C. B., et al. (2023). Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound. Brain 146 (3), 865–872. Epub 2023/01/26. doi:10.1093/brain/awac459
Partridge, B., Eardley, A., Morales, B. E., Campelo, S. N., Lorenzo, M. F., Mehta, J. N., et al. (2022). Advancements in drug delivery methods for the treatment of brain disease. Front. Vet. Sci. 9, 1039745. Epub 2022/11/05. doi:10.3389/fvets.2022.1039745
Rezai, A. R., D'Haese, P. F., Finomore, V., Carpenter, J., Ranjan, M., Wilhelmsen, K., et al. (2024). Ultrasound blood-brain barrier opening and aducanumab in Alzheimer's disease. N. Engl. J. Med. 390 (1), 55–62. Epub 2024/01/04. doi:10.1056/NEJMoa2308719
Salvador, E., Kessler, A. F., Domröse, D., Hörmann, J., Schaeffer, C., Giniunaite, A., et al. (2022). Tumor treating fields (TTFields) reversibly permeabilize the blood-brain barrier in vitro and in vivo. Biomolecules 12 (10), 1348. Epub 2022/10/28. doi:10.3390/biom12101348
Sonabend, A. M., Gould, A., Amidei, C., Ward, R., Schmidt, K. A., Zhang, D. Y., et al. (2023). Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. Lancet Oncol. 24 (5), 509–522. Epub 2023/05/05. doi:10.1016/s1470-2045(23)00112-2
Tanzhu, G., Chen, L., Xiao, G., Shi, W., Peng, H., Chen, D., et al. (2022). The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell. Death Discov. 8 (1), 416. Epub 2022/10/12. doi:10.1038/s41420-022-01206-y
Terstappen, G. C., Meyer, A. H., Bell, R. D., and Zhang, W. (2021). Strategies for delivering therapeutics across the blood-brain barrier. Nat. Rev. Drug Discov. 20 (5), 362–383. Epub 2021/03/03. doi:10.1038/s41573-021-00139-y
Uchida, Y., Kan, H., Sakurai, K., Arai, N., Inui, S., Kobayashi, S., et al. (2020). Iron leakage owing to blood-brain barrier disruption in small vessel disease CADASIL. Neurology 95 (9), e1188–e1198. Epub 2020/06/27. doi:10.1212/wnl.0000000000010148
Uchida, Y., Kan, H., Sakurai, K., Horimoto, Y., Hayashi, E., Iida, A., et al. (2022). APOE ɛ4 dose associates with increased brain iron and β-amyloid via blood-brain barrier dysfunction. J. Neurol. Neurosurg. Psychiatry 93, 772–778. Epub 2022/04/29. doi:10.1136/jnnp-2021-328519
Keywords: BBB, pharmacology, BBB imaging, drug, neurology, Alzheimer disease
Citation: Peng J, Han Y and Wang L (2024) Opening neural gateways: old dog now has new tricks. Front. Pharmacol. 15:1389383. doi: 10.3389/fphar.2024.1389383
Received: 21 February 2024; Accepted: 11 June 2024;
Published: 01 July 2024.
Edited by:
Josipa Vlainic, Rudjer Boskovic Institute, CroatiaReviewed by:
Yuto Uchida, Johns Hopkins Medicine, United StatesFrancisca Pérez-Severiano, Instituto Nacional de Neurología y Neurocirugía MVS y, Mexico
Copyright © 2024 Peng, Han and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yong Han, hanyine@gmail.com; Ligang Wang, wangligang@hmc.edu.com